shire map
Select a

Shire Global


Steven Gillis, PhD

Steven GillisNon-Executive Director

Appointed: October 1, 2012

Committee membership: Audit, Compliance & Risk Committee, Remuneration Committee and Science & Technology Committee

Skills & experience: Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners; a provider of venture capital for technology firms. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation. An immunologist by training Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his PhD from Dartmouth College.

Key appointments: ARCH Venture Partners (Managing Director), Pulmatrix, Inc. (Non-Executive Director), PhaseRx Inc. (Chairman and Non-Executive Director) and VBI Vaccines Inc. (Chairman and Non-Executive Director).

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice.��Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE